| dc.description |
<div class="h6 abstract-title" style="margin: 0px 0px 0.25rem; padding: 0px 0px 0.25rem; font-size: 2.125rem; font-family: franklin_gothic, "Helvetica Neue", Helvetica, Arial, sans-serif; line-height: 1.2; -webkit-font-smoothing: antialiased; color: rgb(28, 28, 28); letter-spacing: normal;">Abstract</div><p style="margin-bottom: 1.25rem; padding: 0px; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 16px; line-height: 1.8; text-rendering: optimizelegibility; -webkit-font-smoothing: antialiased; color: rgb(28, 28, 28);"><span style="font-weight: 600; line-height: inherit;">Purpose: </span>: To investigate the effect of octreotide, a somatostatine analogue,<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>in experimental diabetes model and persistent clinical cystoid<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>macular edema<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"></span></p><p style="margin-bottom: 1.25rem; padding: 0px; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 16px; line-height: 1.8; text-rendering: optimizelegibility; -webkit-font-smoothing: antialiased; color: rgb(28, 28, 28);"><span style="font-weight: 600; line-height: inherit;">Methods: </span>: Three groups of rabbits including control group (10 rabbits),<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>diabetes group (10 rabbits with alloxan-induced diabetes), and<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>treatment group (10 rabbits with alloxan-induced diabetes and<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>treatment with subcutaneous octreotide 2,5mg, twice a day) were<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>studied with light and transmission electron microscopy after<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>3 months of follow-up. Clinical treatment arm included retrospective<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>review of charts of 4 patients who had persistent cystoid macular<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>edema, unresponsive to all interventions including antiVEGFs<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>treated with posterior subtenon octreotide (Sandostatin-LAR®,10mg).<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>They had BCVA of less than 20/200, and OCT(Stratus<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;">TM</span>)-based<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>central macular thickness (CMT) of more than 600 micron.<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"></span></p><p style="margin-bottom: 1.25rem; padding: 0px; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 16px; line-height: 1.8; text-rendering: optimizelegibility; -webkit-font-smoothing: antialiased; color: rgb(28, 28, 28);"><span style="font-weight: 600; line-height: inherit;">Results: </span>: When compared to treatment group, diabetes group had leukocyte<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>infiltration nearby the capillary loss, extensive loss of the<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>pericytes, severe disruption in the basal membrane, and significant<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>degree of the endothelial edema. When compared to control group,<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>treatment group had only significant degree of capillary dilation.<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>Three patients completed 6 months follow-up after 1 injection.<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>Relative changes in CMT ranged from 10 to 35 percent, and 2<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>eyes obtained BCVA of 20/100. No adverse effects including laboratory<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>parameters was recorded.<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"></span></p><p style="margin-bottom: 1.25rem; padding: 0px; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 16px; line-height: 1.8; text-rendering: optimizelegibility; -webkit-font-smoothing: antialiased; color: rgb(28, 28, 28);"><span style="font-weight: 600; line-height: inherit;">Conclusions: </span>: With its long-acting release formula, octreotide may provide<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>a novel treatment option for cases suffering from otherwise<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>untreatable clinically significant diabetic macular edema. Further<span style="font-size: 12px; line-height: 0; position: relative; vertical-align: baseline; top: -0.5em;"> </span>studies are needed.</p> |
|